Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 27295
IPSCIO Record ID: 27346
IPSCIO Record ID: 294016
IPSCIO Record ID: 2357
A. Soft Tissue Includes Gore patch products used in the following applications
i) Reconstruction of hernias and soft tissue deficiencies, such as abdominal wall defects, diaphragmatic hernia, laparoscopic hernia, pelvic floor and lid reconstruction, ventral hernia, laparoscopic inguinal hernia, muscle flap reconstruction, vaginal prolapse, rectal prolapse, scrotal hernia, gastric banding and temporary facial bridging; and
ii) Plastic and reconstructive surgery, such as malarplasty, mentoplasty, rhinoplasty, maxilloplasty, frontal defects, reconstructive lip augmentations, orbital repair, facial folds, facial slings and auricuoplasty.
B. Cardiovascular Includes Gore patch products used in cardiovascular and cardiac patching, such as carotid patch, angioplasty, profundaplasty, AV access graft patching, septal defects, outflow tracts, aneurysm repair and other patch angioplasty.
C. Surgical Membrane/Adhesion Limiting Includes Gore patch products used in the following applications
i) Reconstruction or repair of the peritoneum, where minimal adhesions to a prosthetic material are desired, such as infertility surgery, gynecological surgery and gynecological and surgical oncology;
ii) Temporary or permanent prosthesis for the repair of dura mater during neurosurgery, such as tumor resection, tethered cord releases, trauma repair and Chiari decompression;
iii) Reconstruction of the pericardium where minimal adhesions are desired; and
iv) Wrap for pedicled arterial conduits.
IPSCIO Record ID: 286596
Licensor grants to Licensee exclusive, perpetual, sub-licensable rights to Licensorâ€™s IP, Trade Marks (TM), and all technical knowhow to manufacture, distribute, market and commercialize the product in all countries outside the Territory if in any country outside the Territory that Licensor grants to Licensee and Licensee pays for any or all patent related costs or files for registration or files for regulatory approvals, CE certification, preclinical and clinical studies.
Licensor hereby appoints Licensee as an exclusive Distributor of the Product for the Territory in the Field of Use. As such, Licensee shall have the authority to purchase, market and sell the Product in the Territory in the Field of Use. Licensee may not Actively Promote Sales (e.g. through promotion, advertising, or by establishing branches or distribution depots) outside of the Territory. Furthermore, Licensee may only Actively Promote Product for the Field of Use. Licensee hereby accepts such appointment and agrees to use its best efforts to maximize sales of the Product in the Territory in the Field of Use. Licensee acknowledges that Licensees right to distribute is for the Territory in the Field of Use only.
DuraGraft â€“ Vascular Conduit Solution- For use in Cardiac and Peripheral Bypass Grafting with Arteries and Veins and For Vascular Surgeries. The product DuraGraft is a two-component system. Licensor will produce product component A and B either as bulk product or in separate containers ready for packaging to Licensee. Licensor will assist Licensee at Licenseeâ€™s cost, with technology transfer to allow Licensee to complete the manufacturing of the DuraGraft product at its ISO13485 certified site in the Territory or and release the product for commercial use in Licensee territories. Licensor will transfer all Intellectual Property and technologies to manufacture for the currently marketed liquid and the solid dosage form (powder formulation) that requires final development and scale up, of DuraGraft formulations to enable Licensee to manufacture the products at their manufacturing facilities for supply in the Territory.
A CE Marked Product â€“ Notified Body is BSI, Netherlands
Trademarks shall refer to any trademark used by Licensor in connection with the Product, whether derived from common law use, from registration or from statutory protection against unfair competition, including without limitation those rights to Licensorâ€™s corporate name, other trade names, model names and trademarks, including DURAGRAFT.
Intellectual Property and technologies are to manufacture for the currently marketed liquid and the solid dosage form (powder formulation) that requires final development and scale up, of DuraGraft formulations to enable Licensee to manufacture the products at their manufacturing facilities for supply in the Territory.
DuraGraft is a vascular graft treatment that improves clinical outcomes by reducing the incidence and complications of graft failure.